SA58, a new anti-COVID-19 monoclonal antibody nasal spray, has shown favorable efficacy in preventing COVID-19 infection, said two preliminary reports.
To test the efficacy and safety of the spray, which was developed by China's Sinovac Life Sciences Co, clinical studies were conducted with medical personnel working in designated COVID-19 hospitals and makeshift hospitals in the city of Hohhot in North China's Inner Mongolia Autonomous Region, as well as with voluntary workers from 21 construction sites in Beijing.
The effectiveness of SA58 in preventing infection among Hohhot's medical staff was as high as 77.7 percent, and SA58 was able to lower the risk of COVID-19 infection by 61.83 percent among the study participants in Beijing, said the research results published on medRxiv, a preprint server for health sciences.
While the data has shown satisfactory efficacy and safety of SA58 in reducing symptomatic COVID-19 infections in healthy adults with early exposure within 72 hours, it cannot yet represent other kinds of groups including the elderly and people with underlying diseases.
SA58 has advantages over intramuscular injections, as it is less invasive and more acceptable to recipients. It is also convenient for medical personnel and other high-risk groups to use, said the research.
